Full Press Release Details
Vice President, Investor Relations & Corporate Affairs
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
Aliso Viejo, CA - February 20, 2025 - Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include:
"Our record fourth quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
Fourth Quarter 2024 Financial Results
Net sales in the fourth quarter of 2024 of $105.5 million increased 28%, both on a reported and constant currency basis, compared to $82.4 million in the same period in 2023.
Gross margin for the fourth quarter of 2024 was approximately 73%, compared to approximately 77% in the same period in 2023. Non-GAAP gross margin for the fourth quarter of 2024 was approximately 82%, compared to approximately 84% in the same period in 2023.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2024 increased 9% to $69.0 million, compared to $63.0 million in the same period in 2023. Non-GAAP SG&A expenses for the fourth quarter of 2024 increased 10% to $68.6 million, compared to $62.3 million in the same period in 2023.
GAAP and non-GAAP research and development (R&D) expenses for the fourth quarter of 2024 decreased 1% to $36.5 million, compared to $37.1 million in the same period in 2023.
Loss from operations in the fourth quarter of 2024 was $28.7 million, compared to operating loss of $38.6 million in the fourth quarter of 2023. Non-GAAP loss from operations in the fourth quarter of 2024 was $18.3 million, compared to non-GAAP operating loss of $32.4 million in the fourth quarter of 2023.
Net loss in the fourth quarter of 2024 was $33.6 million, or ($0.60) per diluted share, compared to net loss of $36.8 million, or ($0.75) per diluted share, in the fourth quarter of 2023. Non-GAAP net loss in the fourth quarter of 2024 was $22.2 million, or ($0.40) per diluted share, compared to non-GAAP net loss of $30.6 million, or ($0.63) per diluted share, in the fourth quarter of 2023.
Full Year 2024 Financial Results
Net sales in 2024 of $383.5 million increased 22%, both on a reported and constant currency basis, compared to $314.7 million in 2023.
Gross margin for 2024 was approximately 75%, compared to approximately 76% in 2023. Non-GAAP gross margin for 2024 was approximately 82%, compared to approximately 83% in 2023.
SG&A expenses in 2024 increased 17% to $261.2 million, compared to $224.1 million in 2023. Non-GAAP SG&A expenses in 2024 increased 17% to $258.6 million, compared to $221.2 million in 2023.
GAAP and non-GAAP R&D expenses in 2024 decreased 2% to $136.4 million, compared to $138.8 million in 2023.
Loss from operations in 2024 was $122.4 million, compared to operating loss of $128.7 million in 2023. Non-GAAP loss from operations in 2024 was $93.3 million, compared to non-GAAP operating loss of $103.8 million in 2023.
Net loss in 2024 was $146.4 million, or ($2.77) per diluted share, compared to net loss of $134.7 million, or ($2.78) per diluted share, in 2023. Non-GAAP net loss in 2024 was $98.3 million, or ($1.86) per diluted share, compared to non-GAAP net loss of $109.7 million, or ($2.27) per diluted share, in 2023.
Included in non-GAAP loss from operations, non-GAAP net loss and non-GAAP EPS for 2024 and 2023 are acquired IPR&D charges of $14.2 million and $5.0 million, respectively, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.27) and ($0.11) in each of these respective periods.
The company ended the fourth quarter of 2024 with approximately $324 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.
2025 Revenue Guidance
The company expects 2025 net sales to be in the range of $475 million to $485 million based on the latest foreign currency exchange rates.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company's financial outlook. A link to the webcast is available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (international) and enter Conference ID 7935742. A replay of the webcast will be archived on the company's website following completion of the call.
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the "Financials & Filings - Quarterly Results" section titled "Quarterly Summary." This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details
the key facts associated with the quarter, the state of the company's business objectives and strategies and any forward statements or guidance the company may make. This document is provided alongside the company's earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. As such, today's conference call will be in a format primarily consisting of a questions and answers session, during which Glaukos will address any queries investors have regarding the company's results. It is the company's goal that this format will make its quarterly earnings process more efficient and impactful for the investment community going forward.
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR therapy; the impact of general macroeconomic conditions including foreign currency fluctuations and future health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject W, iAccess, iStent infinite, iDose TR, our corneal cross-linking products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents,
and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission (SEC), including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the SEC on November 5, 2024, and our Annual Report on Form 10-K for the year ended December 31, 2024, which is expected to be filed with the SEC by March 3, 2025. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) ("Non-GAAP Purposes"). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements. See "GAAP to Non-GAAP Reconciliations" for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates
in effect in the comparable prior period. See "Reported Sales vs. Prior Periods" for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended | Year Ended | ||||||||||||
| December 31, | December 31, | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||
| Net sales | $ | 105,499 | $ | 82,365 | $ | 383,481 | $ | 314,711 | |||||
| Cost of sales | 28,635 | 18,891 | 94,027 | 75,575 | |||||||||
| Gross profit | 76,864 | 63,474 | 289,454 | 239,136 | |||||||||
| Operating expenses: | |||||||||||||
| Selling, general and administrative | 69,003 | 63,034 | 261,166 | 224,068 | |||||||||
| Research and development | 36,527 | 37,062 | 136,425 | 138,768 | |||||||||
| Acquired in-process research and development | - | 2,000 | 14,229 | 5,000 | |||||||||
| Total operating expenses | 105,530 | 102,096 | 411,820 | 367,836 | |||||||||
| Loss from operations | (28,666) | (38,622) | (122,366) | (128,700) | |||||||||
| Non-operating (expense) income : | |||||||||||||
| Interest income | 2,494 | 2,912 | 11,105 | 9,164 | |||||||||
| Interest expense | (1,572) | (3,428) | (10,040) | (13,633) | |||||||||
| Charges associated with convertible senior notes | - | - | (18,012) | - | |||||||||
| Other (expense) income, net | (5,950) | 2,420 | (6,288) | (558) | |||||||||
| Total non-operating (expense) income | (5,028) | 1,904 | (23,235) | (5,027) | |||||||||
| Loss before taxes | (33,694) | (36,718) | (145,601) | (133,727) | |||||||||
| Income tax (benefit) provision | (114) | 61 | 771 | 934 | |||||||||
| Net loss | $ | (33,580) | $ | (36,779) | $ | (146,372) | $ | (134,661) | |||||
| Basic and diluted net loss per share | $ | (0.60) | $ | (0.75) | $ | (2.77) | $ | (2.78) | |||||
| Weighted-average shares outstanding used to compute basic and diluted net loss per share | 55,584 | 48,876 | 52,755 | 48,433 |
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
| December 31, | December 31, | ||||||
| 2024 | 2023 | ||||||
| (unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 169,626 | $ | 93,467 | |||
| Short-term investments | 149,289 | 201,964 | |||||
| Accounts receivable, net | 60,744 | 39,850 | |||||
| Inventory | 57,678 | 41,986 | |||||
| Prepaid expenses and other current assets | 12,455 | 18,194 | |||||
| Total current assets | 449,792 | 395,461 | |||||
| Restricted cash | 4,733 | 5,856 | |||||
| Property and equipment, net | 97,867 | 103,212 | |||||
| Operating lease right-of-use asset | 30,254 | 27,146 | |||||
| Finance lease right-of-use asset | 41,816 | 44,180 | |||||
| Intangible assets, net | 263,445 | 282,956 | |||||
| Goodwill | 66,134 | 66,134 | |||||
| Deposits and other assets | 20,715 | 15,469 | |||||
| Total assets | $ | 974,756 | $ | 940,414 | |||
| Liabilities and stockholders ' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 13,026 | $ | 13,440 | |||
| Accrued liabilities | 62,099 | 60,574 | |||||
| Total current liabilities | 75,125 | 74,014 | |||||
| Convertible senior notes | - | 282,773 | |||||
| Operating lease liability | 33,936 | 30,427 | |||||
| Finance lease liability | 69,463 | 70,538 | |||||
| Deferred tax liability, net | 6,928 | 7,144 | |||||
| Other liabilities | 22,373 | 13,752 | |||||
| Total liabilities | 207,825 | 478,648 | |||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of December 31, 2024 and 2023 | - | - | |||||
| Common stock, $0.001 par value; 150,000 shares authorized; 56,472 and 49,148 shares issued and 56,444 and 49,120 shares outstanding at December 31, 2024 and 2023, respectively | 56 | 49 | |||||
| Additional paid-in capital | 1,509,831 | 1,059,751 | |||||
| Accumulated other comprehensive income | 2,615 | 1,165 | |||||
| Accumulated deficit | (745,439) | (599,067) | |||||
| Less treasury stock (28 shares as of December 31, 2024 and 2023) | (132) | (132) | |||||
| Total stockholders' equity | 766,931 | 461,766 | |||||
| Total liabilities and stockholders' equity | $ | 974,756 | $ | 940,414 |
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
| Q4 2024 | Q4 2023 | ||||||||||||||||||
| GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | ||||||||||||||
| Cost of sales | $ | 28,635 | $ | (9,972) | (a)(b) | $ | 18,663 | $ | 18,891 | $ | (5,523) | (a) | $ | 13,368 | |||||
| Gross Margin | 72.9 | % | 9.4 | % | 82.3 | % | 77.1 | % | 6.7 | % | 83.8 | % | |||||||
| Operating expenses: | |||||||||||||||||||
| Selling, general and administrative | $ | 69,003 | $ | (411) | (c) | $ | 68,592 | $ | 63,034 | $ | (705) | (c) | $ | 62,329 | |||||
| Loss from operations | $ | (28,666) | $ | 10,383 | $ | (18,283) | $ | (38,622) | $ | 6,228 | $ | (32,394) | |||||||
| Non-operating (expense) income: | |||||||||||||||||||
| Other (expense) income, net | $ | (5,950) | $ | 951 | (d) | $ | (4,999) | $ | 2,420 | $ | - | $ | 2,420 | ||||||
| Net loss | $ | (33,580) | $ | 11,334 | (e) | $ | (22,246) | $ | (36,779) | $ | 6,228 | (e) | $ | (30,551) | |||||
| Basic and diluted net loss per share | $ | (0.60) | $ | 0.20 | $ | (0.40) | $ | (0.75) | $ | 0.12 | $ | (0.63) |
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
| Full Year 2024 | Full Year 2023 | ||||||||||||||||||
| GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | ||||||||||||||
| Cost of sales | $ | 94,027 | $ | (26,541) | (a)(b) | $ | 67,486 | $ | 75,575 | $ | (22,092) | (a) | $ | 53,483 | |||||
| Gross Margin | 75.5 | % | 6.9 | % | 82.4 | % | 76.0 | % | 7.0 | % | 83.0 | % | |||||||
| Operating expenses: | |||||||||||||||||||
| Selling, general and administrative | $ | 261,166 | $ | (2,526) | (c) | $ | 258,640 | $ | 224,068 | $ | (2,820) | (c) | $ | 221,248 | |||||
| Loss from operations | $ | (122,366) | $ | 29,067 | $ | (93,299) | $ | (128,700) | $ | 24,912 | $ | (103,788) | |||||||
| Non-operating expense: | |||||||||||||||||||
| Charges associated with convertible senior notes | $ | (18,012) | $ | 18,012 | (d) | $ | - | $ | - | $ | - | $ | - | ||||||
| Other expense, net | $ | (6,288) | $ | 951 | (e) | $ | (5,337) | $ | (558) | $ | - | $ | (558) | ||||||
| Net loss | $ | (146,372) | $ | 48,030 | (f) | $ | (98,342) | $ | (134,661) | $ | 24,912 | (f) | $ | (109,749) | |||||
| Basic and diluted net loss per share | $ | (2.77) | $ | 0.91 | $ | (1.86) | $ | (2.78) | $ | 0.51 | $ | (2.27) |
| Reported Sales vs. Prior Periods (in thousands) | ||||||||||||||||||||||
| Year-over-Year Percent Change | Quarter-over-Quarter Percent Change | |||||||||||||||||||||
| 4Q 2024 | 4Q 2023 | 3Q 2024 | Reported | Operations (1) | Currency (2) | Reported | Operations (1) | Currency (2) | ||||||||||||||
| International Glaucoma | $ | 27,869 | $ | 21,857 | $ | 24,467 | 27.5 | % | 28.7 | % | (1.2) | % | 13.9 | % | 16.4 | % | (2.5) | % | ||||
| Total Net Sales | $ | 105,499 | $ | 82,365 | $ | 96,670 | 28.1 | % | 28.4 | % | (0.3) | % | 9.1 | % | 9.8 | % | (0.7) | % |
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period's average foreign exchange rates
| Reported Sales vs. Prior Periods (in thousands) | |||||||||||||
| Year-over-Year Percent Change | |||||||||||||
| 2024 | 2023 | Reported | Operations (1) | Currency (2) | |||||||||
| International Glaucoma | $ | 103,705 | $ | 85,560 | 21.2 | % | 23.0 | % | (1.8) | % | |||
| Total Net Sales | $ | 383,481 | $ | 314,711 | 21.9 | % | 22.4 | % | (0.5) | % |
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period's average foreign exchange rates